Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Maven Clinic vs Omada Health

Maven Clinic
Graded #383

Higher grade

vs+2.3999999999999986
Omada Health
Graded #435

Lower grade

The verdict

Maven Clinic takes it — 58/100 to 55.6/100.

Maven Clinic grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maven Clinic is a virtual women's and family health platform (fertility, maternity, menopause, pediatrics) used by 2,300+ employers that also runs a dedicated GLP-1 Care program.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
45
45
Dose & formulationMaven Clinic +13
53
40
Clinical oversightEven
77
77
Labs & monitoringOmada Health +8
53
61
FulfillmentMaven Clinic +8
70
62
Contract termsEven
55
55
Maven Clinic · left barOmada Health · right bar

The numbers

MetricMaven ClinicOmada Health
WeighScore58/10055.6/100
GradeCC
Scorecard rank#383#435
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Maven Clinic

Graded #383 · C

Strengths

  • Dedicated GLP-1 Care program with brand-name (FDA-approved) GLP-1 prescriptions
  • On-demand visits with metabolic and hormone-health specialists, plus nutrition and strength support
  • Integrated with broader women's, hormone, and family health care
  • LegitScript-verified; trusted by 2,300+ employers
  • Available as both an employer health benefit and a consumer self-pay option

Where it loses points

  • Pricing is not published on the public site
  • Primarily distributed through employers and health plans — direct access can depend on your plan
  • US state availability for GLP-1 is not specified publicly
  • Brand-name only — no lower-cost compounded option
Omada Health

Graded #435 · C

Strengths

  • Added GLP-1 prescribing and medication management in late 2025
  • Clinicians trained in obesity care, available in all 50 states
  • Behavioral support wrapped before, during and after treatment
  • GLP-1 Flex Care adds a cash-pay medication pathway in 2026
  • Publicly traded, evidence-based virtual care platform

Where it loses points

  • Core program distributed via employers and health plans, limited cash-pay
  • GLP-1 prescribing is a recent addition still scaling
  • GLP-1 Flex Care only rolling out to employers later in 2026
  • No transparent published price for the core member program

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard